ClinicalTrials.gg
Active, not recruitingNCT01453660Updated Nov 4, 2026

Acute Changes in Endothelial Function in Germ Cell Tumor Patients Treated With Cisplatin and Untreated Germ Cell Tumor Controls

An observational study in Germ Cell Cancer, sponsored by Memorial Sloan Kettering Cancer Center. Active, not recruiting at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Memorial Sloan Kettering Cancer Center · Observational

How we know

Updated Nov 4, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
44
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 94 studies in Neoplasms, Germ Cell and Embryonal with a site in United States — 25 open to participants now, 36 under way, 3 of them phase 3. Neoplasms, Germ Cell and Embryonal · United States.

Planned enrollment
9th of 13
44 · median 213
Started
2011
with 2 others
Observational
13 of 94
4 open now
Primary completion
2027-10
later than 15 of 35 live
Registered
21st of 94
by date
Lead sponsor
5 of 94
Memorial Sloan Kettering Cancer Center

Among the 94 studies in Neoplasms, Germ Cell and Embryonal with a site in United States, this one is the 9th largest by planned enrollment of the 13 observational ones that give a count, is one of 3 that started in 2011, is one of 13 observational ones, reaches primary completion later than 15 of the 35 other live ones, and was the 21st registered.

Neoplasms, Germ Cell and Embryonal

167 studies on the registry are indexed under Neoplasms, Germ Cell and Embryonal; 49 are open to participants now.

Browse Neoplasms, Germ Cell and Embryonal studies →

Open to participants now

25 of the 94 studies in Neoplasms, Germ Cell and Embryonal with a site in United States are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 40 Neoplasms, Germ Cell and Embryonal studies recruiting now, 20 (50%) set no upper age limit and 16 (40%) stop at 75 or younger; 22 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies in Neoplasms, Germ Cell and Embryonal with a site in United States, or all of them as a file.
02

Study summary

Cisplatin is one of the most common chemotherapy drugs used to treat many different cancers, including germ cell tumors (GCT). Cisplatin is very effective in treating GCT, but there are side effects. One of the possible long-term side effects of cisplatin is thought to be heart disease. The way that cisplatin causes heart disease is not well understood. One possibility is that cisplatin may damage the inside layer of blood vessels called the endothelium. The purpose of this study is to measure changes in the endothelium that happen when patients with GCT get cisplatin chemotherapy and to compare these changes with a group of patients not receiving chemotherapy.

03

Conditions studied

  • Germ Cell Cancer

Keywords

  • Endothelial Function
  • Endo-PAT2000 system
  • 11-140
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The Cisplatin-Based Chemotherapy Group will be recruited from the Genitourinary (GU) oncology clinics. The GU Oncology section has a large clinical service which ensures adequate recruitment.

The Surgery-Only Group will consist of patients with a diagnosis of GCT who have recently had surgical management of their disease and are not planned to receive radiation or chemotherapy. Potentially eligible patients will be recruited from the GU Oncology and Urology clinics since they are seen by both services.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Cisplatin-Based Chemotherapy Group

  • -proven diagnosis of GCT
  • Male
  • Age ≥18
  • No prior exposure to chemotherapy or radiation
  • Planned to receive 3-4 cycles of cisplatin-based chemotherapy

Surgery-Only Group

  • Histologically-proven diagnosis of GCT Male
  • Age ≥18
  • Surgical management of GCT performed less than 90 days before start of study (includes orchiectomy and primary retroperitoneal lymph node dissection (RPLND))
  • No prior exposure to chemotherapy or radiation

Exclusion criteria

Exclusion Criteria:

Cisplatin-Based Chemotherapy Group

  • Prior exposure to chemotherapy or radiation
  • Known diagnosis or history of being diagnosed with vasculitis, autonomic dysfunction, coronary artery disease, or collagen-vascular disease

Surgery-Only Group

  • Prior exposure to chemotherapy or radiation
  • Planned for non-surgical management with chemotherapy or radiation.
  • Known diagnosis or history of being diagnosed with vasculitis, autonomic dysfunction, coronary artery disease, or collagen-vascular disease.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
44 participants (estimated)
Biospecimen retention
Samples without dna

Groups and cohorts

  • Cisplatin-Based Chemotherapy Group

    GCT patients who are planned to start cisplatin-based chemotherapy will be identified within the genitourinary oncology service clinics and offered inclusion in the trial.

    Other: Endo-PAT2000 testing

  • Surgery-Only Group

    GCT patients who have been treated with surgery and who do not require chemotherapy or radiation will be used as a comparison group to confirm that there is not a significant change in endothelial function among GCT patients treated with surgery alone.

    Other: Endo-PAT2000 testing

Interventions

  • OtherEndo-PAT2000 testing

    Endo-PAT2000 testing is done six times during the study. Baseline Assessment Time 1 Cycle 1, Day 1 (Pre-chemotherapy)Time 2 Cycle 1, Day 1 (After 1st dose of cisplatin), Time 3 Cycle 1, Day 2 (Before second cisplatin dose of cycle 1), Time 4 Cycle 1, Day 5 (After last cisplatin dose of cycle 1), End-of-Study Assessment Time 5 (14-34 weeks from Time 1; e.g., 1-12 weeks following completion of the last cycle of first-line chemotherapy) Long-Term Follow Up Assessment Time 6 (24-30 months from Time 1)

  • OtherEndo-PAT2000 testing

    Time 1: A baseline assessment will be performed in the fasting state including Endo-PAT2000, vital signs, waist circumference, fasting blood draw, \& urine sample. This will be considered Day 1 of the study for this group of patients. Time 2 (2-5 hours from Time 1): Two to five hours after Time 1, patients will undergo assessment of blood pressure \& heart rate, including orthostatics \& Endo-PAT2000 testing. Time 5 -- End of Study visit (14-34 weeks from Time 1): At a time point 14 to 34 weeks later than Time 1 patients will undergo study testing in the fasting state. This includes Endo-PAT2000 testing, vital signs including orthostatics, waist circumference, fasting blood draw, \& urine sample. The Surgery-Only Group will not have any assessment at Time 3 (Day 2) or Time 4 (Day 5) due to logistical concerns. Long-Term Follow Up Assessment Time 6 (24-30 months following Time 1)

    Also known as: For any patients in Surgery-Only Group who relapse & enroll in the the, Cisplatin-Based Chemotherapy Group before the completion of the Surgery Group, End of Study Assessment, the Baseline Time 1 Chemotherapy Group Assessment can, will also serve as the End of Study Time 5 Surgery Group Assessment.

06

What researchers measure

Primary outcomes

  1. Measure the endothelial reactivity (PAT-RH) in both groups

    The Endo-PAT quantifies the endothelium-mediated changes in vascular tone, elicited by a 5-minute occlusion of the brachial artery (using a standard BP cuff).

    Time frame: 15 minutes

Secondary outcomes

  1. Identify sociodemographic

    (age, race/ethnicity)

    Time frame: 2 years

  2. Identify comorbid health conditions

    Other laboratory studies being assessed in this trial will include lipid profile, testosterone, LH, FSH, and hemoglobin A1C. These tests are being evaluated to determine if there are concurrent comorbidities

    Time frame: 2 years

  3. Measure PAT-RH index

    at Time 6 (Long-Term Follow Up Assessment) in the Cisplatin-Based Chemotherapy Group and evaluate long term changes in PATRH index.

    Time frame: 2 years

07

Study locations

1 site
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Oct 2011 (actual). Primary completion is estimated for Oct 2027, 192 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Oct 2026 → Oct 2027 and completion Oct 2026 → Oct 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2011
First posted
Oct 18, 2011
StartActual
Oct 11, 2011
Primary completionEst.
Oct 2027was Oct 2026
CompletionEst.
Oct 2027was Oct 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 2026→Oct 2027
Nov 4, 2026
Study completion
Oct 2026→Oct 2027
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Primary completion Oct 2026→Oct 2027
    Study completion Oct 2026→Oct 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT01453660
Responsible party
Sponsor
First posted
Oct 18, 2011
Start date
Oct 11, 2011
Primary completion
Oct 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Nov 4, 2026

Study contacts

Darren Feldman, MD
principal investigator · Memorial Sloan Kettering Cancer Center
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion